Also, when we characterized the splicing alterations in small-cell lung cancer, a tumor type with low survival and with limited response to immune therapy, self-epitope depletion occurs much more frequently than splicing-neoepitope production, and we could validate many of them from MHC-associated mass spectrometry in lymphocytes. The gene discussed is HLA-C; the disease is neoplasm.